BCD-248
- Generic Name
- BCD-248
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Biocad
- Target Recruit Count
- 100
- Registration Number
- NCT06668792
- Locations
- 🇷🇺
State budgetary healthcare institution of the Sverdlovsk region "Sverdlovsk regional clinical hospital â„–1", Ekaterinburg, Russian Federation
🇷🇺SBHI of the Kaliningrad region "Central City Clinical Hospital", Kaliningrad, Russian Federation
🇷🇺SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigala", Kazan, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath